Trial Identifier: | D081KC00001 |
Sponsor: | AstraZeneca |
Collaborator: |
IQVIA (formerly QuintilesIMS)
|
NCTID:: | NCT02734004 |
Start Date: | March 2016 |
Primary Completion Date: | September 2021 |
Study Completion Date: | September 2025 |
Condition: | Breast Cancer; Gastric Cancer; Ovarian Cancer; Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
Country | Location |
---|---|
CH | Chur, CH, CH-7000 |
CH | Lausanne, CH, 1011 |
FR | Bordeaux Cedex, FR, 33076 |
FR | Caen Cedex 05, FR, 14076 |
FR | Clermont Ferrand cedex 01, FR, 63011 |
FR | Dijon cedex, FR, 21079 |
FR | Marseille CEDEX 5, FR, 13385 |
FR | Nantes, FR, 44202 |
FR | Paris cedex 14, FR, 75014 |
FR | Pierre Benit CEDEX, FR, 69495 |
FR | Toulouse Cedex 9, FR, 31059 |
FR | Villejuif Cedex, FR, 94805 |
GB | Cambridge, GB, CB2 0QQ |
GB | Dundee, GB, DD1 9SY |
GB | Glasgow, GB, G12 0YN |
GB | Greater London, GB, SW3 6JJ |
GB | London, GB, SE1 9RY |
GB | London, GB, NW1 2PG |
GB | Manchester, GB, M20 4BX |
GB | Newcastle Upon Tyne, GB, NE7 7DN |
GB | Sutton, GB, SM2 5PT |
IL | Haifa, IL, 91096 |
IL | Jerusalem, IL, 91031 |
IL | Petah Tikva, IL, 49100 |
IL | Ramat Gan, IL, 5265601 |
IL | Tel Aviv, IL, 6423906 |
KR | Goyang-si, KR, 10408 |
KR | Seongnam-si, KR, 13620 |
KR | Seoul, KR, 06273 |
KR | Seoul, KR, 135-710 |
KR | Seoul, KR, 06591 |
KR | Seoul, KR, 03722 |
KR | Seoul, KR, 03080 |
KR | Seoul, KR, 05505 |
NL | Amsterdam, NL, 1066 CX |
NL | Amsterdam, NL, 1081 HV |
NL | Maastricht, NL, 6229 HX |
NL | Nijmegen, NL, 6525 GA |
NL | Rotterdam, NL, 3075 EA |
NL | UTRECHT, NL, 3584 CX |
US, GA | Newnan, GA, US, 30265 |
US, MA | Boston, MA, US, 02114 |
US, MD | Towson, MD, US, 21204 |
US, MI | Detroit, MI, US, 48202 |
US, MO | Saint Louis, MO, US, 63110 |
US, OH | Hilliard, OH, US, 43026 |
US, PA | Philadelphia, PA, US, 19104 |